Browsing Tag
IgA nephropathy
16 posts
Primary IgA nephropathy : FDA grants full approval to Travere Therapeutics’ Filspari
In a groundbreaking move, the US Food and Drug Administration (FDA) has granted full approval to Travere Therapeutics’…
Novartis’ atrasentan shows significant reduction in proteinuria in seasonal allergic rhinitis patients
Novartis presented compelling interim results from the Phase III ALIGN study evaluating the efficacy of atrasentan, an investigational…
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9bn in strategic expansion
In a major development in the biotechnology industry, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc.…
Novartis to expand renal portfolio with Chinook Therapeutics acquisition
Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington…
Chinook Therapeutics gets orphan drug status from EC for atrasentan in IgAN
Chinook Therapeutics, a US-based biopharma company, has secured orphan drug designation for atrasentan from the European Commission (EC)…
Calliditas Therapeutics initiates Phase 3 NEFIGARD trial for Nefecon to treat IgA nephropathy
Swedish pharmaceutical company Calliditas Therapeutics has initiated the Phase 3 NEFIGARD trial to evaluate its lead drug candidate,…